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ABSTRACT 
Management approaches in emergency department (ED) patients with acute heart failure (AHF) 
have largely focused on intravenous diuretics. Yet, the primary pathophysiological derangement 
underlying AHF in many patients is not volume overload. Patients with hypertensive AHF (H-
AHF) represent a clinical phenotype with distinct pathophysiologic mechanisms that lead to 
elevated ventricular filling pressures. To optimize treatment response and minimize adverse 
events in this subgroup of patients, clinical management likely needs to be tailored to a 
conceptual model of disease that is based on these mechanisms. This consensus paper 
reviews the relevant pathophysiology, clinical characteristics, approach to therapy, and 
considerations for clinical trials in ED patients with H-AHF.  
PATHOPHYSIOLOGY OF HYPERTENSION IN ACUTE HEART FAILURE 
Hypertensive AHF (H-AHF) is defined as pulmonary congestion in the setting of a systolic blood 
pressure over 160 mmHg.[1] Many patients with H-AHF have a history of poorly controlled 
hypertension.[2] The consequences of longstanding hypertension include changes to both the 
vasculature as well as the ventricle, resulting in increased stiffness and reduced compliance 
across the cardiovascular system. [3]  Such stiffening increases systolic load on the left 
ventricular myocardium, triggering intra- and extra-cellular adaptations that tend to normalize 
systolic and diastolic sarcomere stress.[1] Many of these changes occur at the expense of left 
ventricular compliance and ultimately lead to clinically significant diastolic dysfunction. [4] [5]  As 
the functional ventricular-vascular relationship becomes uncoupled, the left ventricle has 
insufficient cardiac reserve to compensate for the increases in afterload and preload that 
accompany hypertensive episodes, exertion and muscle contraction. [6] As a result, the poorly 
compliant cardiovascular system with chronic hypertension responds with larger changes in left 
ventricular filling pressure for a given change in preload or afterload.[7] Thus, it is important that 
therapy for H-AHF includes interventions to both improve vascular compliance and reduce 
intravascular filling pressure. 
VASCULAR DYSFUNCTION AND ITS ROLE IN ACUTE HEART FAILURE  
Normal cardiovascular function requires close integration between the heart and vasculature to 
provide adequate distribution to the vital organs and periphery.[8] A compliant aorta acts as a 
capacitor, reducing the peak pressure generated during ventricular systole and promoting 
continuous forward flow throughout the cardiac cycle. Central aortic pressure is further 
augmented during diastole by the reflected pressure wave generated downstream at the 
junction of the medium and small resistance arterioles. These reflected waves effectively 
represent the recoil of arteriolar expansion resulting from the force of contraction during systole. 
The net effect is a dynamic process of ventricular-arteriolar coupling that serves as a major 
determinant of cardiac output, providing a mechanism for adaptive changes in response to 
metabolic needs.[8] 
In patients with chronic hypertension the aorta and large arteries stiffen, enhancing the 
amplitude and velocity of the reflected pulse wave generated by resistance arterioles.[9] 
Arterioles also adapt to chronic increases in arterial pressure associated with hypertension 
through smooth muscle hypertrophy; a process that normalizes end-arteriolar pressure at the 
expense of a further increase in large artery pressure and increased pulse wave velocity. The 
reflected wave, which normally reaches the central aorta after aortic valve closure, can increase 
velocity enough to return to the proximal aorta in late systole. This results in increased load for 
ventricular contraction and may trigger early aortic valve closure.  An immediate consequence 
of shortened left ventricular systole due to premature aortic valve closure is increased diastolic 
volume and pressure, resulting in increased pulmonary venous pressures, predisposing the 
patient to pulmonary congestion.  
Hypertension contributes to vascular stiffness and increases left ventricular afterload. 
Further increases in vasoconstriction may precipitate H-AHF. Increases in sympathetic tone 
leading to vasoconstriction can be seen in instances such as: 1) physical exertion (via central 
command and the muscle-metabolic reflex) [10]; 2) hypoxia associated with acute respiratory 
infection; 3) chronic obstructive pulmonary disease; 4) obstructive sleep apnea; 5) pulmonary 
hypertension; 6) psychosocial stress/anxiety; 7) substance abuse (e.g. cocaine); or 8) abrupt 
cessation of antihypertensive medication.  
 
BLOOD PRESSURE AND ITS RELATIONSHIP TO ACUTE HEART FAILURE  
Large registries have shown that heart failure patients are most commonly hypertensive upon 
presentation to the ED. [11, 12]  (Table 1). Moreover, the initial systolic blood pressure is a 
strong predictor of outcomes, with an association between higher presenting blood pressures 
and lower in-hospital mortality, 30-day myocardial infarction, death, or rehospitalization, as well 
as a greater likelihood of discharge within 24 hours.[13, 14] These associations are  likely 
corresponding anatomic implications and contractile reserve, as higher systolic blood pressure 
[15] is more often linked to heart failure with preserved ejection fraction, with the likelihood of an 
ejection fraction >40% increasing 3% for every 1 mmHg presenting systolic blood pressure 
>120 mmHg (Table 2). 
However, patients presenting with AHF can manifest a wide range of blood pressures. 
While there is a clear association between presenting blood pressure and outcomes, there is no 
direct relationship between blood pressure and ejection fraction, which explains why patients 
with AHF across the spectrum of underlying cardiac function can appear similar clinically. 
Ultimately, blood pressure summarizes cardiac contractile force relative to the vascular 
resistance it encounters.[16, 17] On the ventricular side, ejection capability is determined by 
myocardial function, while on the vascular side, resistance to flow reflects arterial health, the 
degree of vasoconstriction resulting from neurohormonal stimulation, and volume status.  
Blood pressure largely determines organ perfusion. Maintenance of blood pressure is 
tightly regulated by baroreceptors, primarily in the aorta and carotid arteries, though renal 
mechanisms are also involved. Changes in cardiac output and systemic vascular resistance are 
triggered by sympathetic nervous system and neurohormonal activation in response to 
baroreceptor mediated detection of alterations in vascular pressure. Thus, when confronted with 
increased arterial resistance, a heart with normal contractile reserve is able to maintain cardiac 
output with a net increase in systolic blood pressure.[18, 19] However, in the setting of chronic 
hypertension and heart failure, baroreceptor responses shift to be more tolerant to greater tonic 
pressure and expected responses to acute perturbations may be altered. [20-22] This 
contributes to a ventricular-vascular uncoupling, where acute changes in blood pressure 
associated with excess venous return or vasoconstriction are not met with the same cardiac 
contractile response. As a result, a poorly functioning myocardium is unable to maintain cardiac 
output in response to elevated systemic vascular resistance, making elevated blood pressure a 
de facto impediment to forward flow.  
 
INTRAVASCULAR VOLUME AND ITS ROLE IN ACUTE HEART FAILURE  
Elevated cardiac filling pressures are a hallmark of patients presenting the AHF. While total 
body sodium and water retention has traditionally been implicated as the main driver for 
elevated filling pressures, recent studies have shown that many patients do not gain weight prior 
to AHF onset.[23] [24] This has led investigators to suggest that redistribution rather than net 
volume gain is an important mechanism underlying AHF, likely driven by perturbations of the 
autonomic nervous system.[25] This finding is supported by studies showing changes in heart 
rate variability occurring weeks prior to presentation for AHF, a time during which cardiac filling 
pressures begin to rise, in the absence of a change in weight, and prior to the development of 
symptoms. [26] Thus, while symptoms drive most patients with HF to seek treatment, there is at 
least a moderate degree of discordance between symptoms, cardiac filling pressures, and 
intravascular volume.  
Signals activating vasoconstriction induce acute and subacute increases in intravascular 
volume and contribute to the pulmonary congestion of H-AHF.  Neurohormonal factors 
associated with chronic heart failure activate renal sodium and water retention leading to 
increase in intra- and extra-vascular volume. This may be accompanied by abrupt redistribution 
of blood volume from venoconstriction, especially in the splanchnic vascular bed, mobilization of 
fluid into the central and pulmonary circulation, and a dramatic rise in intravascular volume from 
an acute surge in sympathetic tone. Such increases in filling volume also trigger the Frank-
Starling mechanism in the right ventricle (RV), which combines a catecholamine mediated 
increase in RV contractile force to drive up pulmonary artery and capillary wedge pressure. [27]  
While abnormal volume distribution is responsible for many of the cardinal signs and 
symptoms of AHF, the history and physical exam findings of dyspnea, elevated jugular venous 
pulse, S3 gallop, hepato-jugular reflux and peripheral edema have low sensitivity for detecting 
volume overload.[28] Direct measurement of blood volume using a radionucleotide-dilution 
technique demonstrated a wide range of fluid distribution patterns in subjects with AHF and low 
ejection fraction,[29] with most, though not all, showing elevated total body volume. With a net 
diuresis of 8.4±5.2 liters, the majority of fluid loss was from the interstitial compartment, 
accounting for 85±15% of the total fluid reduction, with only a slight decrease in intravascular 
volume despite patients being clinically judged to be euvolemic. Therefore, trans-capillary 
mobilization of interstitial fluid is responsible for the weight reduction during treatment for AHF, 
with little impact on intravascular volume 
Zelis et al explored this link between fluid status, hypertension and heart failure in a 
canine model where the arterial sodium and water content were pathologically elevated over 
control animals.[30] The elevation of tissue sodium and water content, specifically vascular 
tissue, was found to be the likely mechanism for increased arteriolar stiffness and thus decrease 
capacitance in heart failure. This was then studied in a human model using mineralocorticoid-
induced sodium and water retention [31]. These findings laid the groundwork for the theory that 
decreased arteriolar capacitance in AHF is driven by elevated tissue sodium and water and may 
serve as a therapeutic target. Studies suggest residual intravascular hypervolemia portends a 
poor prognosis. In 43 clinically compensated chronic HF patients, 65% were found to have 
expansion of the intravascular space using the labelling technique.[32] Increased total body 
volume was associated with lower systolic blood pressure, increased pulmonary capillary wedge 
pressure and increased risk of death or transplantation at one year. This suggests a diuresis 
endpoint, such as subcutaneous edema, is misleading and not representative of intravascular 
congestion. 
OTHER CONSIDERATIONS  
Age: HF is predominantly a condition of the older population in developed countries where the 
prevalence increases markedly with age, rising sharply at age 75.[33] Elderly patients, 
particularly women are more likely than younger adults to develop heart failure with preserved 
ejection fraction, elevated systemic vascular resistance, and impaired ventricular-arteriolar 
coupling.[34] Pulmonary edema in the setting of severe systolic hypertension is a common 
presentation of AHF in patients with advanced age. Evidence supporting treatment options 
targeted for elderly patients is limited by their exclusion from and underrepresentation in 
randomized trials in the acute care setting. 
 
Renal Function: Chronic kidney disease is common and associated with persistent congestion 
during AHF, and portends worse prognosis. [35] Approximately 30% of patients with heart 
failure have moderate to severe renal impairment.[36] Maladaptive mechanisms that contribute 
to progressive renal disease are also important therapeutic targets in the management of H-
AHF. In chronic kidney disease, activation of the renin-angiotensin-aldosterone system leads to 
a compensatory increase in filtration fraction but at the expense of intraglomerular hypertension, 
hypertrophy and sclerosis of remaining nephrons. Detrimental effects of renin-angiotensin-
aldosterone system activation extend to the myocardium and the vasculature, contributing to the 
pathophysiology in both chronic HF and H-AHF. ACE-inhibitors or angiotensin receptor blockers 
are widely recommended for patients with renal insufficiency and AHF unless renal dysfunction 
is severe [37]. However, patients with heart failure with reduced ejection fraction and severe 
renal insufficiency (creatinine clearance <30 mL/min) who were treated in-hospital with a renin-
angiotensin-aldosterone system antagonist appear to have been better 1-year survival, [38] 
suggesting that such an approach should not be absolute. Despite this, ACE-inhibitors and 
angiotensin receptor blockers are administered less frequently during heart failure 
hospitalizations in patients with severe kidney dysfunction, [39, 40] and more data are needed if 
current recommendations and clinical practice are to be altered. Mineralocorticoid receptor 
antagonists have been shown in subgroup analyses to confer mortality benefit in patients with 
renal dysfunction and moderate to severe heart failure.[41] Mineralocorticoid receptor 
antagonists are recommended in patients with reduced ejection fraction and a creatinine <2.5 
mg/dL[37, 42]. Further studies are required to clarify the benefit these medications might confer 
early in the course of AHF management. 
Worsening renal function during AHF is of particular concern in those with baseline renal 
insufficiency. Diuretics and vasodilators are commonly used to achieve pulmonary 
decongestion, but may be associated with the risk of increasing renal dysfunction. Higher doses 
of diuretics have been associated with worsening renal function in patients with AHF, [43] and 
activation of the renin-angiotensin-aldosterone system has been suggested as a possible 
underlying mechanism. This may be of greater importance in patients with H-AHF, where 
volume redistribution may be more prominent than volume overload. While higher levels of 
diuretics may be required to achieve decongestion in patients with renal dysfunction, blood 
pressure control is also important. Improving symptoms and avoiding hypovolemia is crucial in 
this cohort. Patients with AHF and comorbid renal disease should be monitored for large and 
persistent increases in serum creatinine during and after inpatient diuresis. 
TREATMENT  
Expert opinion, supplemented by small cohort and randomized studies, suggests initial therapy 
might best be informed by clinical parameters rather than a typical diuretic-only approach.[44-
46] While there is no randomized trial evidence evaluating initial treatment strategies for patients
with AHF based on hemodynamics, systolic blood pressure plays a central role in AHF as a 
predictor of morbidity and mortality.[47] Accordingly, we suggest initial treatment may be most 
effective if it is based on presenting systolic blood pressure.[44, 46, 48-52]  
Stabilization with noninvasive positive pressure ventilation (NIPPV) is useful in patients 
with H-AHF and significant work of breathing. Meta analyses suggest it decreases the need for 
intubation in both ED and hospitalized patients with AHF. [53] [54] A randomized trial of NIPPV 
in the prehospital settting suggests it may not impact mortality or the need for intubation, but it 
does improve work of breathing. [55] Whether it has additive value to aggressive use of 
intravenous vasodilators in H-AHF patients is unclear. [56] 
The OPTIMIZE-HF investigators reported ≈50% of patients with AHF had a systolic 
blood pressure of >140 mmHg at presentation; in-hospital mortality was lowest among those 
with the highest value (between 189-300 mmHg).[47] Intravenous diuretics are the cornerstones 
of AHF therapy.[57] However, the failing heart is sensitive to afterload and some patients may 
develop pulmonary edema with a systolic blood pressure as low as 150 mmHg. Prompt 
recognition and afterload reduction with vasodilators may avoid the need for intubation.[58] Until 
recently, evidence regarding the safety and efficacy of vasodilator therapy in AHF was limited. 
[59, 60] However, data from contemporary studies suggests specific phenotypes of AHF 
patients, such as those with H-AHF benefit from intravenous vasodilators.[50, 51, 61]  
Nitrovasodilators: Nitroglycerin is a short-acting, rapid-onset, venous and arterial dilator. It 
decreases mean arterial pressure by preload reduction, and at higher doses, afterload as well. 
Nitroglycerin has coronary vasodilatory effects, decreasing ischemia and improving cardiac 
function. The choice between intravenous, sublingual, or transdermal routes is often based on 
symptoms. Sublingual is easily administered, rapidly bioavailable, and can be given as needed. 
There is no consensus, but often a 10-20% reduction in blood pressure, leading to reduction in 
filling pressures, is sufficient to improve symptoms of dyspnea. One initial approach is repeated 
administration of a 0.4 milligram sublingual nitroglycerin tablet every 3-5 minutes until symptom 
relief, replacement with intravenous nitroglycerin, or a blood pressure target is reached. 
Transdermal nitroglycerin has been demonstrated to reduce filling pressure in patients with HF 
who had pulmonary artery catheters in place. [62] [63] The available data suggest the 
transdermal ointment has clinical effect within one hour of application, and should be reapplied 
every 6 hours. A typical starting dose is 1-2 mg every 6 hours.  When using the intravenous 
formulation, a starting dose of 0.5 to 0.7 mcg/kg/min is common and titrated upwards every few 
minutes, up to 200-400 mcg/min based on blood pressure (avoiding large drops) and symptoms 
(Tables 3 and 4). High doses (2 mg by repeated intravenous bolus) may be beneficial acutely 
and adverse events are uncommon. [51]  Transdermal nitroglycerin 0.5-2 inches on the chest 
wall is sometimes used, but is hampered by slow onset, should be reserved for after initial 
therapy has improved conditions, or in patients with minor symptoms. Hypotension may occur 
though it is often transient with the intravenous and sublingual forms, and usually resolves after 
cessation of the nitroglycerin. If hypotension is persistent, consideration should be given to 
volume depletion, right ventricular infarct, or an etiology other than AHF causing the current 
symptoms, and a saline fluid bolus may be administered. Headache is frequent and usually 
responds to acetaminophen. Methemoglobinemia is theoretically possible, but typically not a 
concern unless high-doses are used for extended intervals. Despite common use and targeting 
appropriate pathophysiologic derangements, nitroglycerin has little published efficacy evidence 
beyond its effects on symptom resolution.[64] [65]   
 Nitroprusside is a potent arterial and venous vasodilator that produces a decrease in 
blood pressure and left ventricular filling pressure leading to increases in cardiac output. 
Nitroprusside is generally considered to be more effective than nitroglycerin, despite a small 
study comparing LV filling that  suggested their hemodynamic response profiles are similar. [66] 
The initial dose is 0.3 mcg/kg/min, titrated upward every five to ten minutes based on blood 
pressure and clinical response (maximum 10 mcg/kg/min). The major complication is 
hypotension. It is also rarely associated with cyanide toxicity, typically with high doses, 
prolonged (longer than three days) use, and hepatic or renal impairment. Such toxicity can be 
prevented by concurrent administration of sodium thiosulfate. Though uncommonly used in the 
acute setting, a historical goal of nitroprusside therapy is rapid reduction of systemic vascular 
resistance and wedge pressure in an effort to prevent the need for endotracheal intubation. 
Logistical considerations related to the need for close monitoring, often with an arterial line 
and/or in the intensive care unit setting and keeping the infusion protected from light make it 
less convenient to use.  
 
Loop Diuretics: With vasodilator therapy and blood pressure control, patients may require 
diuretics (Table 4) based on continued symptoms or evidence of excess fluid accumulation. As 
discussed previously, not all patients with H-AHF are volume overloaded, therefore routine 
diuretic administration may not be necessary when treating this phenotypic variant. Moreover, 
diuretics administered alone without vasodilators for H-AHF may increase mortality [50] and 
worsen renal function. Successful management of blood pressure and filling pressure often 
results in marked improvement in respiratory status before any diuresis. Furosemide has been 
used most commonly, but alternatives including bumetanide (1 mg equivalent to 40 mg 
furosemide) or torsemide (20 mg equivalent to 40 mg furosemide) can also be used. All trigger 
rapid diuresis after an intravenous dose, often within 10 to 15 minutes.  
 
Natriuretic Peptides: Smaller studies have shown a benefit of nesiritide (exogenous b-type 
natriuretic peptide) on dyspnea relief, but the pivotal mortality trial [67] found no significant 
difference in rehospitalization or mortality. Although initial studies did not demonstrate any 
increased risk of hypotension, hypotensive events were over 2 hours duration in the VMAC 
trial[68], and the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart 
Failrue (ASCEND-HF) study reported an increased risk of both symptomatic and asymptomatic 
hypotension in patients randomized to nesiritide.[67] This may have occurred because the 
ASCEND-HF study did not specifically target H-AHF, with a mean baseline systolic blood 
pressure of enrolled patients of 124 mm Hg. Nesiritide does not result in substantial clinical 
improvement when added to standard care and is a second line agent, utilized when 
nitroglycerin is ineffective or contraindicated. Carperitide has also been studied in AHF patients 
with systolic blood pressure above 90 mmHg. While small studies suggest it may have efficacy 
and it is used in other parts of the world, it is not currently available in the United States. [69] 
[70]  
 
Calcium Channel Blockers: Clevidipine is a rapidly acting intravenous calcium channel blocker 
that lowers blood pressure by selective arteriolar vasodilation and, without venous capacitance 
effects, increases cardiac output as peripheral vascular resistance declines. It is metabolized in 
the blood and has a one-minute half-life, allowing for rapid titration. Because it has no negative 
inotropic or chronotropic effects it may be beneficial in H-AHF. In a trial of patients presenting 
with H-AHF, clevidipine was demonstrated to be more effective than nitroglycerin or nicardipine 
for rapid control of blood pressure and dyspnea relief.[52] This trial was open label and there 
have been concerns about reflex tachycardia and increased atrial fibrillation, which will need to 
be addressed in large scale trials. [71] 
ACE Inhibitors and Angiotensin Receptor Blockers: The use of these drugs has received 
widespread adoption for hypertension and chronic heart failure, however the utility of 
intravenous formulations for AHF is understudied. While studies of intravenous ACE inhibitors 
for pulmonary edema unrelated to infarction and H-AHF suggest safety and beneficial 
hemodynamic effects, and their properties make them attractive for consideration in the acute 
setting, their small sample sizes and settings limit extrapolation to the emergency care setting. 
[64] 
Contraindications and Alternatives to Vasodilation in Select Settings: Because all 
vasodilators lower blood pressure they are not recommended if there are signs of hypoperfusion 
or existing hypotension. Flow-limiting, preload-dependent states such as right ventricular 
infarction, aortic stenosis, hypertrophic obstructive cardiomyopathy, anaphylaxis or volume 
depletion increase the risk of hypotension associated with vasodilator use.[72] Combined with 
acute pulmonary edema, these pre-load dependent states can be extremely difficult to manage. 
Therapy is aimed at decreasing the outflow gradient by reducing heart rate and cardiac 
contractility. Although this can be accomplished with intravenous β-blockers, some prefer this to 
be done with invasive hemodynamic guidance.  
CONSIDERATIONS FOR CLINICAL TRIAL DESIGN 
Similar to other biomarkers, use of systolic blood pressure as a criterion for inclusion or 
exclusion efficiently discriminates AHF patients. Thus clinical trials use systolic blood pressure 
in conjunction with other criteria to identify patients that will ideally have the most benefit and 
least risk to a novel therapy. Another consideration for clinical trial enrollment is whether H-AHF 
is the primary cause of symptoms, or a secondary cause as a result of another primary problem 
such as acute hypertension, worsening renal function or acute coronary syndrome. Recent trials 
of novel agents with vasodilatory properties have reported precipitous drops in blood pressure 
may lead to worse outcomes, and have used higher systolic blood pressure inclusion criteria. 
[61, 73] Importantly, vasodilation may be the cause of some poor outcomes; in large trials 
spanning multiple sites and countries, hypotension in patients who may not have AHF or only 
mild heart failure may precipitate sufficient adverse events to offset any potential benefits of a 
novel therapy. 
 The upper limit of systolic blood pressure for entry into clinical trials has also been 
debated. Patients with very high systolic blood pressure (>185mmHg) tend to improve quickly 
with appropriately dosed nitrate therapy, making symptom improvement beyond standard care 
difficult. Focusing enrollment on such patients would thus make conduct of clinical trials 
especially challenging as prompt dyspnea resolution may preclude eligibility if mechanisms to 
identify potential subjects early in the course of treatment are not in place. Further, a rapid 
response to usual therapy makes it more difficult to achieve a clinically significant effect size. 
This highlights a paradox in AHF that the sickest appearing patient at presentation may have 
the best outcome, e.g. flash pulmonary edema. While aggressive management is required, 
treatment usually results in rapid improvement. In contrast, a patient with AHF patient and 
advanced HF may have a low systolic blood pressure at presentation and present with milder 
symptoms, such as fatigue and dyspnea on exertion, yet these patients are at the greatest risk 
for adverse events.  
Other vasodilators are generally prohibited in clinical trials at the time of enrollment or 
allowed only at lower doses. Despite their infrequent use in practice, the absence of ‘head-to-
head’ comparisons of novel agents vs. traditional vasodilators (i.e. nitrates) in patients with very 
high systolic blood pressure is a frequent criticism, raising questions as to whether the novel 
agent is truly going against usual standard therapy. Regardless, the ideal systolic blood 
pressure range for both current and novel therapies has yet to be determined. Studies such as 
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) study [74] 
that have targeted patients with systolic blood pressures > 125 mm Hg, have shown both 
clinical and biomarker evidence of benefit with novel agents (e.g., serelaxin, a vasomodulator 
with favorable renal blood flow properties), suggesting that there may be effect modification 
within phenotypic subgroups. Table 5 shows the more recent AHF trials and their systolic blood 
pressure entry criteria as well as time of enrollment.  
 
CONCLUSION AND FUTURE DIRECTIONS 
The hallmark of patients presenting to the ED with H-AHF is an altered relationship between 
ventricular and vascular function, leading to reduced cardiovascular reserve and an inability to 
adequately accommodate increases in venous return. Arterioles also adapt to chronic increases 
in arterial pressure associated with hypertension, resulting in an increased load for ventricular 
contraction triggering early aortic valve closure.  An immediate consequence of shortened left 
ventricular systole due to premature aortic valve closure is increased diastolic volume and 
pressure. Subsequent increases in pulmonary venous pressures may result in pulmonary 
congestion. Many of these patients are older with concomitant renal disease. Preliminary data 
raises the possibility that future treatment might be better focused on preload and afterload 
reduction with vasodilators rather than volume removal with diuretics. Clinical trial design has 
begun to account for patients with H-AHF by raising the minimum blood pressure to be enrolled, 
thus limiting the proportion of patients who are likely to develop symptomatic hypotension. 
Results from several clinical trials will be available in the next few years and will provide insight 
into safety and efficacy in this cohort. It is still unclear whether an upper blood pressure limit is 
necessary, but reasons to exclude may be more a function of logistics rather than clinical 
concern. Future investigations should investigate a diuretic sparing approach in this cohort, as 
the pathophysiology strongly supports volume redistribution rather than volume overload. The 
lower limit of blood pressure for clinical trial enrollment should be investigated to determine the 
optimal response to investigational agents in this cohort of patients. Similarly, further data are 
needed to assess the similarities and differences the pathophysiology and management of H-
AHF with heart failure and reduced versus preserved ejection fraction.[7]  
Table 1. Systolic Blood Pressure On Presentation In Acute Heart Failure  
Dataset N Hospitals SBP mmHg 
 (IQR) 
SBP >140 mmHg 
(%) 
SBP <90 mmHg 
(%) 
ADHERE [12] 107,362 274 144±33 50 3 
OPTIMIZE 
[47] 
48,612 259 143±33 50 -- 
GWTG-HF 110,621 275 138 
(118,159) 
-- -- 
 SBP = systolic blood pressure 
Table 2. Heart Failure with Preserved Ejection Fraction by Presenting Blood Pressure 
 












Table 3: Suggested Management of Hypertensive Acute Heart Failure⁺  
Stepwise Approach Comments 
1. Administer oxygen as needed to keep saturation 95% or greater, give sublingual nitroglycerin. Sublingual nitroglycerin may 
be repeated up to one per 
minute 
2. If severe dyspnea, consider NIV or intubation.  
3. If blood pressure >150/100 mm Hg, add IV nitroglycerin or nitroprusside; if blood pressure falls below 100 mm Hg, 
stop nitrates, monitor for persistent hypotension or symptoms. If blood pressure<150/100 after sublingual 
administration and if improved, consider transdermal nitroglycerin. 
See text for discussion of 
these agents. 
4. Start IV loop diuretic (furosemide or bumetanide or torsemide) in the setting of volume overload.  Initiate nitrates before 
diuretics. 
5. Assess for severity of illness/high risk: altered mental status persistent, hypoxia despite NIV, hypotension, 
troponin elevation, ischemic ECG changes, blood urea nitrogen over 43, creatinine over 2.75, tachycardia, 
tachypnea, or inadequate urine output. 
 
6. Admit to ICU if high severity of illness or risk of decompensation.  
7. Choose discharge or emergency department observation unit admission if good response to therapy and no need 
for on-going intravenous vasodilators, no high-risk features, and good social support. Admit the rest, ICU if any 
ongoing cardiorespiratory compromise or acute ischemia. 
Scoring systems may not 
reliably identify all patients at 
risk. 
Abbreviations: blood pressure = blood pressure; NIV = noninvasive ventilation; systolic blood pressure = systolic blood pressure. 
*Adapted from Collins SP, Storrow AB[72] ⁺ Inclusion: systolic blood pressure >140 mm Hg 
 
  
Table 4: First-Line Medications for Acute Heart Failure 
 
Vasodilators for Acute Heart Failure 
Vasodilator Dose Titration End Point Complications 
Sublingual NTG 0.4 milligram every 1–5 min Blood pressure Hypotension 
Transdermal NTG 1-2 mg of topical NTG every 6 hours Blood pressure Possible prolonged hypotension 
IV NTG 0.5–0.7 microgram/kg/min (starting dose) Symptoms Headache, hypotension  
Nitroprusside 0.3 microgram/kg/min (starting dose), 10 
micrograms/kg/min (maximum) 
Blood pressure Hypotension, cyanide/thiocyanate 
toxicity, coronary steal Symptoms 
Diuretics for Heart Failure 
Diuretic Dose (IV) Effect Complications 
Furosemide No prior use: 20-40 mg IVP Diuresis starts within 15–20 min ↓ K+, ↓ Mg2+, hyperuricemia, 
hypovolemia 
If prior use: total daily IV dose 1  to 2.5 times the 
patient’s previous total daily oral dose, divided in half 
and given IV bolus every 12 hours 
Duration of action is 4–6 h 
Ototoxicity, prerenal azotemia, 
sulfa allergy 
If no effect by 20–30 min, increase subsequent dose 
Bumetanide 1–3 milligrams IV Diuresis starts within 10 min Same as above 
Peak action at 60 min  
Torsemide 10–20 milligrams IV Diuresis starts within 10 min Same as above 
Peak action in 1–2 h  
Abbreviations: IVP = IV push; NTG = nitroglycerin; ↓ = decreased. *Used with permission from Collins SP, Storrow AB[72] 
Table 5. Selected Acute Heart Failure Vasodilator Clinical Trials   
Trial And  
Intervention 
Year N Systolic Blood Pressure Criteria Enrolment Dyspnea as 
endpoint 
VERITAS [75, 76] 
Tezosentan v Placebo 
2007 1448 (1453)* EXCL: < 100mmHg or < 120mmHg 
in patients receiving a vasodilator 
After admission (within 24 hours Yes 
(Primary) 
OPTIME-CHF[77] 
Milrinone v Placebo 




Nesiritide v Nitrates v 
Placebo  
2002 489 EXCL: < 90mmHg After admission (no specific time 
window except need for 





Tolvaptan v Placebo 
2007 Trial A = 
2048, Trial B 
= 2085 






2007 1327 EXCL: systolic blood pressure < 
85mmHg 










Serelaxin (4 doses) 
Placebo  
2009 234 INCL: >125mmHg Within 16 h of presentation, 
including time spent in the 
emergency department 




Rolofylline v Placebo 
2010 2033 INCL: ≥ 95mmHg Within 24 hours hospital 
presentation, including time spent in 
the emergency department 
Yes (part of 
composite) 
ASCEND-HF[67] 
Nesiritide v Placebo 
2011 7141 EXCL: < 100mmHg or  < 
110mmHg if on IV nitrates 




Cinanciguat (3 doses) v 
Placebo 
2012 160 planned 
(halted early) 




2012 1161 INCL: > 125mmHg < 16 hours from presentation Yes (primary) 
ATOMIC AHF 
Omecamtiv mecarbil (3 




600 INCL: > 90mmHg  Yes (primary) 
DOSE-AHF[59] 
Differing dosing strategies of 
diuretics 
2011 308 EXCL: < 90mmHg Within 24 hours presentation Yes (secondary) 
PRONTO  
Clevidipine v 
Standard therapy vasodilators 
2012 104 INCL: >160 mmHg  Yes (secondary) 
ROSE-AHF[84] 
Dopamine v Nesiritide (both low 
dose) 
2013 360 EXCL: < 90mmHg Within 24 hours of presentation Yes (secondary) 







2152 INCL: ≥116 and < 180 mmHg Within 12 hours of presentation No 
BLAST-AHF[73] 









Enrolling 6800 planned 
(event driven)
INCL: ≥ 125mmHg Within 16 hours of presentation or 
first IV loop diuretic dose 
Yes (composite 
secondary) 
*VERITAS was discontinued before full enrolment due to improbability of achieving significant treatment effect. The n listed is the planned 
enrolment.  VAS = visual analog scale, NA = not available (information generated from abstract only)
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